1 week Ago By ABMN Staff
Barclays PLC boosted its stake in shares of Surmodics, Inc. ( NASDAQ:SRDX – Free Report ) by 21.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The firm owned 108,001 shares of the company’s stock after purchasing an additional 19,251 shares during the period. Barclays PLC’s holdings in Surmodics were worth $4,278,000 at the end of the most recent reporting period. A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SRDX.
Modus Advisors LLC purchased a new stake in Surmodics during the fourth quarter valued at approximately $40,000. R Squared Ltd purchased a new stake in Surmodics during the fourth quarter valued at approximately $55,000. Legal & General Group Plc increased its holdings in Surmodics by 34.
2% during the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock valued at $137,000 after buying an additional 880 shares during the last quarter. Polymer Capital Management US LLC purchased a new stake in shares of Surmodics in the fourth quarter worth $255,000.
Finally, SG Americas Securities LLC increased its stake in shares of Surmodics by 22.1% in the fourth quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock worth $275,000 after purchasing an additional 1,255 shares in the last quarter.
Institutional investors own 96.63% of the company’s stock. Analyst Ratings Changes A number of analysts have recently issued reports on the stock.
Lake Street Capital raised shares of Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research note on Friday, March 7th. StockNews.
com initiated coverage on shares of Surmodics in a report on Monday, February 3rd. They issued a “hold” rating on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research report on Thursday, January 30th.
Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $50.00.
Surmodics Trading Up 0.2 % Shares of SRDX stock opened at $29.46 on Monday.
Surmodics, Inc. has a 12-month low of $25.17 and a 12-month high of $42.
44. The company has a current ratio of 5.45, a quick ratio of 4.
29 and a debt-to-equity ratio of 0.26. The stock’s 50-day moving average price is $30.
00 and its 200-day moving average price is $35.19. The stock has a market capitalization of $421.
16 million, a price-to-earnings ratio of -29.17 and a beta of 1.30.
Surmodics ( NASDAQ:SRDX – Get Free Report ) last issued its earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.
08) by $0.04. Surmodics had a negative return on equity of 4.
39% and a negative net margin of 11.48%. Equities research analysts predict that Surmodics, Inc.
will post 0.2 EPS for the current fiscal year. Surmodics Company Profile ( Free Report ) Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally.
It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). Featured Stories Want to see what other hedge funds are holding SRDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surmodics, Inc.
( NASDAQ:SRDX – Free Report ). Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter .
.
